Sam Altman

With roughly $500M under management, Sam Altman ranks among the active investors in the AI space. That capital is deployed across their portfolio of AI-focused bets.

Across their portfolio, Sam Altman has consistently backed companies in AI, Nuclear Energy, Biotech. These focus areas reflect where the firm sees the strongest risk-adjusted returns in AI.

Awaira currently tracks 1 companies in Sam Altman's portfolio. The actual number may be higher, as some early-stage investments are not publicly disclosed.

The firm's sweet spot is Early Stage investing. That said, strong conviction deals can pull them into earlier or later rounds depending on the company.

The most notable deal on record for Sam Altman is Sam Altman is a early-stage venture capital firm headquartered in USA, managing approximately $500M in assets under management. The firm concentrates on AI, Nuclear Energy, Biotech, deploying capital primarily at the early stage level. Notable AI portfolio companies include OpenAI. Sam Altman has participated in 1 funding round tracked by Awaira, deploying capital across AI, Nuclear Energy, Biotech sectors. The firm's investment strategy emphasizes AI applications in healthcare and life sciences. Awaira assigns Sam Altman an investor score of 95/100 based on portfolio strength, AI sector exposure, and market activity. The firm investment thesis centers on identifying AI companies that demonstrate strong technical moats, clear paths to revenue, and potential for category leadership within their respective segments. Sam Altman evaluates opportunities based on team quality, market timing, technology differentiation, and capital efficiency. Portfolio companies including OpenAI reflect the firm emphasis on backing founders who combine deep technical expertise with commercial execution capability.. It is the kind of investment that defines a fund's reputation in the AI ecosystem.